A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer

Inclusion Criteria

• •Males or females at least 18 years of age
• •Diagnosis of NSCLC with locally advanced or metastatic disease
• •Positive for KRAS mutation or Squamous cell histology
• •Previously treated with one platinum-based chemotherapy
• •Disease status must be that of measurable and/or evaluable disease
• •Performance status of 0 to 1 on the ECOG Scale
• •Prior chemotherapy completed at least 3 weeks prior to study enrollment
• •Prior radiation therapy allowed to \< 25% of the bone marrow
• •Patient compliance and geographic proximity that allow adequate follow-up
• •Adequate organ function
• •Patients with reproductive potential must use contraceptive methods
• •Signed informed consent from patient